Entrada Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
TRDA$4.69-4.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $90,394 | $101,211 |
| Marketable securities | 205,304 | 318,787 |
| Restricted cash, current portion | 658 | — |
| Collaboration receivable | 1,177 | 3,680 |
| Prepaid expenses and other current assets | 8,719 | 16,361 |
| Total current assets | 306,252 | 440,039 |
| Property and equipment, net | 7,313 | 10,928 |
| Restricted cash, net of current portion | 3,292 | 3,950 |
| Right-of-use assets, operating leases | 60,451 | 71,120 |
| Other non-current assets | 70 | 284 |
| Total assets | $377,378 | $526,321 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,289 | $4,259 |
| Accrued expenses and other current liabilities | 17,682 | 13,343 |
| Income taxes payable | — | 667 |
| Operating lease obligations, current portion | 4,138 | 7,559 |
| Deferred revenue, current portion | 342 | 13,654 |
| Total current liabilities | 24,451 | 39,482 |
| Operating lease obligations, net of current portion | 46,794 | 51,648 |
| Deferred revenue, net of current portion | — | 6,513 |
| Total liabilities | 71,245 | 97,643 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Common stock, par value $0.0001; 150,000,000 shares authorized; 38,284,221 shares issued and outstanding as of December 31, 2025 and 37,585,944 shares issued and 37,574,538 shares outstanding as of December 31, 2024 | 4 | 4 |
| Additional paid‑in capital | 578,571 | 558,061 |
| Accumulated other comprehensive income (loss) | 652 | (43) |
| Accumulated deficit | (273,094) | (129,344) |
| Total stockholders’ equity | 306,133 | 428,678 |
| Total liabilities and stockholders’ equity | $377,378 | $526,321 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.